Related Experiment Video
Updated: May 11, 2026
08:54
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Innovation in antifungal therapy.
Sarah Dellière1,2, Nicolas Papon3
1Université Paris Cité, AP-HP, Parasitology-Mycology Department, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France. sarah.delliere@aphp.fr.
EMBO Molecular Medicine
|May 9, 2026
Summary
Invasive fungal infections are a growing public health concern, especially for immunocompromised patients. Advances in antifungal therapies offer new hope for managing these challenging infections and combating drug resistance.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Immunology
Background:
- Invasive fungal infections (IFIs) pose a significant public health threat, particularly in immunocompromised individuals.
- High mortality rates (often >50%) and limited systemic antifungal options complicate patient management.
- Emerging antifungal resistance due to overuse/misuse in clinical and agricultural settings exacerbates the challenge.
Purpose of the Study:
- To review recent advances in antifungal therapies for invasive fungal infections.
- To highlight progress in both pathogen-directed and host-directed treatment strategies.
- To underscore the need for novel approaches to combat rising IFIs and resistance.
Main Methods:
- Review of recent literature on medical mycology and antifungal drug development.
- Analysis of pathogen-directed therapies including new compounds, drug repurposing, and novel targets.
- Exploration of emerging host-directed immunomodulatory strategies.
Main Results:
- Significant advancements in identifying new antifungal compounds and drug targets.
- Development of new formulations and repurposing of existing drugs show promise.
- Emerging host-directed therapies leveraging immune responses offer new avenues for treatment.
Conclusions:
- Despite challenges, recent breakthroughs in medical mycology provide hope for improved management of invasive fungal infections.
- A combination of advanced pathogen-directed and novel host-directed strategies is crucial.
- Continued research is essential to overcome antifungal resistance and reduce IFI-related mortality.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...